The Effects of Armillarisin A on Serum IL-1β and IL-4 and in Treating Ulcerative Colitis

详细信息    查看全文

• 作者：Ping Wu ; Yonggao Guo ; Fangyuan Jia ; Xiuli Wang
• 关键词：Ulcerative colitis ; Armillarisin ; IL ; 1β ; IL ; 4
• 刊名：Cell Biochemistry and Biophysics
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：72
• 期：1
• 页码：103-106
• 全文大小：331 KB
• 参考文献：1.Sisi, D., & Keli, D. (2010). The effects of Yuyang enema regimen in treating ulcerative colitis and on serum IL-4 and IL-10. Liaoning University Traditional Chinese Medicine, 12(2), 152-53.
  2.Zhijie, Z., Sheng, X., Gaofeng, M., Wenge, Y., & Xinshan, X. (2011). The effect of traditional Chinese medicine in serum IL-8 and IL-10 in ulcerative colitis patients. Shanxi Traditional Chinese Medicine, 32(5), 566-68.
  3.Qiangmei, C. (2011). The study of the mechanism of the effect of sustained release mesalamine granules on serum IL-6 and TNF-α in ulcerative colitis patients. Clinical Research, 49(36), 34-5.
  4.Ou, Y., Hu, P., Qian, J., Zheng, J., Hu, R.; Chinese Consensus on Diagnosis and Treatment Standard of Inflammatory Bowel Disease. Inflammatory Bowel Disease Collaborative Group, Chinese Medical Association. (2007). Chinese Journal of Gastroenterology, 12(8), 488-95.
  5.Hao, Lijun, Tang, Wenjun, & Zhang, Rongjuan. (2011). Effect of glutamine granules enema on IFN-y, IL-4, IL-8 in patients with ulcerative colitis and observation of clinical efficacy. Chinese Journal of Nosocomiology, 21(22), 4742-744.
  6.Cao, W., Vrees, M. D., Potenti, F. M., Harnett, K. M., Fiocchi, C., & Pricolo, V. E. (2004). Interleukin 1beta-induced production of H2O2 contributes to reduced sigmoid colonic circular smooth muscle contractility in ulcerative colitis. Journal of Pharmacology and Experimental Therapeutics, 311(1), 60-0.PubMed View Article
  7.Mittal, R. D., Bid, H. K., & Ghoshal, U. C. (2005). IL-1 receptor antagonist (IL-1Ra) gene polymorphism in patients with inflammatory bowel disease in India. Scandinavian Journal of Gastroenterology, 40(7), 827-31.PubMed View Article
  8.Wenjie, Y., Yi, L., Wei, X., Le, D., Xiaoting, L., Weiru, J., et al. (2012). The expression characteristics of IL-2, IL-4, IL-17 and IL-10 and the relationships between these cytokines and the severity of ulcerative colitis. Fudan Xuebao, 39(5), 454-59.
  9.Zhaomin, S., & Guoqiang, Z. (2011). The clinical observation of the effect of Armillarisin in treating acute biliary tract infection. Journal of Zhejiang Trauma Surgery, 16(6), 825-26.
  
• 作者单位：Ping Wu (1)
  Yonggao Guo (1)
  Fangyuan Jia (1)
  Xiuli Wang (1)
  
  1. Department of Gastroenterology, Xuzhou Central Hospital, Affiliated Xuzhou Hospital, Medical School of Southeast University, Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, 221009, Jiangsu, China
  
• 刊物主题：Biochemistry, general; Pharmacology/Toxicology; Biotechnology; Cell Biology; Biophysics and Biological Physics;
• 出版者：Springer US
• ISSN：1559-0283

文摘

To study the therapeutic effect of Armillarisin A on patients with ulcerative colitis (UC) and on serum IL-1β and IL-4, sixty patients with UC were randomly divided into three groups: Armillarisin A treatment group (Group I), Armillarisin-combined hormone therapy group (Group II), and hormones treatment as the control group (Group III). Patients in Group I received Armillarisin A 10?mg enema in 100?ml saline. Patients in Group II received Armillarisin A 10?mg and dexamethasone 5?mg enema in 100?ml saline. Patients in Group III received only dexamethasone 5?mg enema in 100?ml saline. The therapeutic efficacy and serum levels of IL-4 and IL-1β were observed. After 4?week treatment, the total effective rates were 90.0?% in Group I and 95.0?% in Group II. Both are higher than it in control group, which was 70.0?%. The serum levels of IL-4 in Groups I and II were significantly higher than it in control group. Compared to IL-4 levels before treatment, the levels of IL-4 after treatment were significantly higher in both Groups I and II. The serum levels of IL-11β were significantly decreased in Groups I and II in comparison to it in control group. Compared to the levels of IL-1β before treatment, the levels of IL-1β were significantly decreased. Armillarisin A shows a significant effect in treating UC. It helps increase IL-4 and lower IL-1β and the mechanism may be related to the body’s immunity regulation.